Axinn Obtains Favorable Decision in FDA Suit

Print
PDF
Email
Share on LinkedIn
Share on X

News | less than 1 min read

January 15, 2013

Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc’s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.

Judge Huvelle’s Memorandum Opinion stated that “the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants.”

Nicholas E.O. Gaglio

Nicholas E.O. Gaglio

Intellectual Property

To subscribe to our publications, click here.

Featured Insights

View all Insights

September 23, 2026

CCWC 22nd Annual Career Strategies Conference

Axinn attorneys Leslie Overton, Denise Plunkett, Jackie Lem, Katrina Rouse, and Monica Smith will speak during the Corporate Counsel Women of Color’s Career Strategies Conference, being held September 23–26 in Orlando, FL.

Sponsorship

September 16, 2026

Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop

Axinn partner Kail Jethmalani will speak on a panel during the Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop. The September 17 panel is titled "Competitor Collaborations or Cartels: Revising the Antitrust Framework for an Algorithmic Age."

Sponsorship

Antitrust

September 15, 2026

Women, Influence, & Power in Law Conference 2026

On September 15, Axinn Partner Mary Helen Wimberly will speak on the "Antitrust in Transition: Risks & Opportunities in a Dynamic Market" panel at ALM"s Women, Influence, & Power in Law Conference, being held September 14–16, 2026 in Nashville, TN.

Sponsorship

Antitrust

August 20, 2026

Axinn Attorneys Earn Top Honors in Best Lawyers 2027

Axinn LLP announced today that nine of its attorneys have been recognized in the 2027 edition of The Best Lawyers in America®, with an additional 18 attorneys named to Best Lawyers: Ones to Watch in America. Partner Matthew S. Murphy was recognized for “Lawyer of the Year” honors in Litigation – Intellectual Property and Litigation – Patent.

News

Antitrust

August 12, 2026

Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg

Axinn advised Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, on the completed sale of its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.

Deals & Cases

Antitrust

August 11, 2026

Benchmark Litigation Honors Axinn Partners on 2026 “40 & Under List”

Axinn is proud to announce that partners James Hunsberger, Kail Jethmalani, and Ali Vissichelli have been named to Benchmark Litigation’s 2026 “40 & Under List.” This annual list recognizes lawyers from across the country who handle significant litigation and have earned the respect of their clients and peers. James, Kail, and Ali were selected based on their work on complex, high-profile matters and their accomplishments in the field.

Awards & Recognitions

Litigation & Trials

August 10, 2026

Axinn Partner Rebecca Clegg Named to Hartford Business Journal’s 2026 40 Under Forty

Axinn partner Rebecca Clegg has been selected as an honoree of Hartford Business Journal’s 2026 40 Under Forty Awards, recognizing forty of Greater Hartford’s most accomplished young professionals for their achievements and contributions to the region.

Awards & Recognitions

Intellectual Property

Featured Insights

© 2026 Axinn LLP. All Rights Reserved

Back to top